Literature DB >> 22303881

Limitations of Chromogranin A in clinical practice.

Vincenzo Marotta1, Vincenzo Nuzzo, Teresa Ferrara, Alfonso Zuccoli, Milena Masone, Lorenzo Nocerino, Michela Del Prete, Francesca Marciello, Valeria Ramundo, Gaetano Lombardi, Mario Vitale, Annamaria Colao, Antongiulio Faggiano.   

Abstract

CONTEXT: Usefulness of circulating Chromogranin A (CgA) for the diagnosis of neuroendocrine tumors (NEN) is controversial. The aim of the present study was to assess the actual role of this marker as diagnostic tool.
METHODS: Serum blood samples were obtained from 42 subjects affected with NEN, 120 subjects affected with non-endocrine neoplasias (non-NEN) and 100 non-neoplastic subjects affected with benign nodular goitre (NNG). Determination of CgA was performed by means of immunoradiometric assay.
RESULTS: The CgA levels among NEN-patients were not significantly different from NNG and non-NEN subjects. The Receiver operating characteristic (ROC) curves analysis failed to identify a feasible cut-off value for the differential diagnosis between NEN and the other conditions.
CONCLUSION: Serum CgA is not helpful for the first-line diagnosis of NEN.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22303881     DOI: 10.3109/1354750X.2012.654511

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  18 in total

1.  The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.

Authors:  I M Modlin; M Kidd; L Bodei; I Drozdov; H Aslanian
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

Review 2.  Consensus on biomarkers for neuroendocrine tumour disease.

Authors:  Kjell Oberg; Irvin M Modlin; Wouter De Herder; Marianne Pavel; David Klimstra; Andrea Frilling; David C Metz; Anthony Heaney; Dik Kwekkeboom; Jonathan Strosberg; Timothy Meyer; Steven F Moss; Kay Washington; Edward Wolin; Eric Liu; James Goldenring
Journal:  Lancet Oncol       Date:  2015-09       Impact factor: 41.316

3.  Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.

Authors:  Somer Matar; Anna Malczewska; Kjell Oberg; Lisa Bodei; Harry Aslanian; Anna Lewczuk-Myślicka; Pier Luigi Filosso; Alejandro L Suarez; Agnieszka Kolasińska-Ćwikła; Matteo Roffinella; Beata Kos-Kudła; Jarosław B Ćwikła; Ignat A Drozdov; Mark Kidd; Irvin M Modlin
Journal:  Neuroendocrinology       Date:  2019-04-16       Impact factor: 4.914

4.  A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.

Authors:  Ivan Kruljac; Ivan Vurnek; Sebastian Maasberg; Davor Kust; Kristina Blaslov; Blaženka Ladika Davidović; Mario Štefanović; Alma Demirović; Alen Bišćanin; Jakša Filipović-Čugura; Jasmina Marić Brozić; Ulrich-Frank Pape; Milan Vrkljan
Journal:  Endocrine       Date:  2018-04-09       Impact factor: 3.633

Review 5.  Biochemical Testing in Neuroendocrine Tumors.

Authors:  Vidya Aluri; Joseph S Dillon
Journal:  Endocrinol Metab Clin North Am       Date:  2017-06-12       Impact factor: 4.741

6.  Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.

Authors:  Masami Miki; Tetsuhide Ito; Masayuki Hijioka; Lingaku Lee; Kohei Yasunaga; Keijiro Ueda; Takashi Fujiyama; Yuichi Tachibana; Ken Kawabe; Robert T Jensen; Yoshihiro Ogawa
Journal:  Jpn J Clin Oncol       Date:  2017-06-01       Impact factor: 3.019

7.  A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors.

Authors:  Magnus Kjellman; Ulrich Knigge; Staffan Welin; Espen Thiis-Evensen; Henning Gronbaek; Camilla Schalin-Jäntti; Halfdan Sorbye; Maiken Thyregod Joergensen; Viktor Johanson; Saara Metso; Helge Waldum; Jon Arne Søreide; Tapani Ebeling; Fredrik Lindberg; Kalle Landerholm; Goran Wallin; Farhad Salem; Maria Del Pilar Schneider; Roger Belusa
Journal:  Neuroendocrinology       Date:  2020-07-28       Impact factor: 4.914

8.  NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis.

Authors:  Anna Malczewska; Kjell Oberg; Beata Kos-Kudla
Journal:  Endocr Connect       Date:  2021-01       Impact factor: 3.335

9.  It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; Aaron T Scott; Po Hien Ear; Chandrikha Chandrasekharan; Andrew M Bellizzi; Joseph S Dillon; Thomas M O'Dorisio; James R Howe
Journal:  Ann Surg Oncol       Date:  2020-07-11       Impact factor: 5.344

Review 10.  Hepatic arterial embolization in patients with neuroendocrine tumors.

Authors:  Michela Del Prete; Francesco Fiore; Roberta Modica; Vincenzo Marotta; Francesca Marciello; Valeria Ramundo; Antonella Di Sarno; Annachiara Carratù; Chiara de Luca di Roseto; Salvatore Tafuto; Fabiana Tatangelo; Robero Baldelli; Annamaria Colao; Antongiulio Faggiano
Journal:  J Exp Clin Cancer Res       Date:  2014-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.